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Summary 
Synthetic peptides corresponding to sequences of HLA class I molecules have inhibitory effects 
on T  cell function. The peptides investigated in this study have sequences corresponding to the 
relatively conserved region of the or1 helix of HLA class I molecules that overlaps the "public 
epitope" Bw4/Bw6. These HLA-derived peptides exhibit inhibitory effects on T  lymphocytes 
and have beneficial effects on the survival ofallogeneic organ transplants  in mice and rats. Pep- 
tides corresponding to the Bw4a epitope appear most potent as they inhibit the differentiation 
of T  cell precursors into mature cytotoxic T  lymphocytes (CTL) and target cell lysis by estab- 
lished CTL lines and clones. To elucidate the mechanism through which these peptides medi- 
ate their inhibitory effect on T lymphocytes, peptide binding proteins were isolated from T  cell 
lysates. We show that the inhibitory Bw4a peptide binds two members of the heat-shock pro- 
tein  (HSP)  70  family,  constitutively expressed HSC70  and  heat-inducible  HSP70.  Peptide 
binding to HSC/HSP70 is sequence specific and follows the rules defined by the HSC70 bind- 
ing  motif.  Most  intriguing,  however,  is  the  strict  correlation of peptide  binding  to  HSC/ 
HSP70 and the functional effects such that only inhibitory peptides bind to HSC70 and HSP70 
whereas  noninhibitory peptides  do  not bind.  This correlation suggests  that  small  molecular 
weight  HLA-derived peptides  may  modulate  T  cell  responses  by  directly interacting with 
HSPs. In contrast to numerous reports of HSP70 expression at the surface of antigen-present- 
ing cells and some tumor cells, we find no evidence that HSC/HSP70 are expressed at the sur- 
face of the affected T  cells. Therefore, we believe that the peptides' immunomodulatory effects 
are  not  mediated  through  a  signaling  event initiated by interaction of peptide  with  surface 
HSP, but favor a model similar to the action of other immunomodulatory compounds, FK506 
and cyclosporin A,  with a  role for HSC/HSP70  similar to that for immunophilins,  FKBPs 
and CyP40. 
T  cell  responses  triggered by polymorphic  differences 
between MHC class I molecules of recipient and do- 
nor tissue  are the major barrier to successful  transplant en- 
graftment.  Despite  advances  in  immunosuppressive  ther- 
apy, acute graft rejection and failure to achieve long-lasting 
graft  acceptance  still  persist.  Thus,  the  ultimate  goal  in 
transplant  biology is  to  achieve long-lasting,  antigen-spe- 
cific unresponsiveness (immunological tolerance). The ben- 
eficial  effect of blood transfusion on the survival of organ 
allografts has been recognized for years (1-3). Although the 
mechanisms  underlying  the  enhancing  effect  of  blood 
transfusion are undoubtedly complex, the contribution of 
soluble HLA class I molecules to induce nonresponsiveness 
to some allografts  is well documented (2,  4,  5).  However, 
studies using soluble HLA have been hindered by the diffi- 
culties in purifying sufficient quantities of material. We and 
others began to investigate the immunomodulatory activi- 
ties of soluble HLA using synthetic peptides corresponding 
to regions of the HLA class I heavy chain that appeared to 
be functionally important. Peptides corresponding to poly- 
morphic sequences of the od and e~2 domains of HLA class 
I molecules were found to inhibit lysis by CTL (6, 7). The 
inhibition was  allele  specific in that a given peptide could 
affect lysis  only  of CTL  specific  for the  HLA  molecule 
from which  it was  derived.  For clinical application  these 
peptides would be oflirmted value, as each donor-recipient 
combination would  require  a  different cocktail  of allele- 
specific peptides.  Synthetic peptides  corresponding to  the 
conserved region of the or  domain of HLA class I mole- 
cules, which is involved in the interaction of HLA class I 
with its  CD8  coreceptor, prevented the  differentiation of 
precursor T  cells into mature CTL, but they failed to in- 
hibit cytolysis of mature CTL (8, 9). 
Recent  studies  using  peptides  corresponding  to  more 
339  J. Exp. Med. ￿9  The Rockefeller University Press ￿9  0022-1007/96/02/339/10  $2.00 
Volume 183  February 1996 339-348 conserved regions in the oil  domain of HLA class I mole- 
cules demonstrated that peptides from the or1 helix (amino 
acid residues 60-84)  also affected T  cell function  (10). The 
activity of these peptides was  mapped to  the  COOH-ter- 
minal ten amino acids and found to correspond to the re- 
gion of the  HLA class I  molecule that  was  recognized in 
early antisera typing studies as the mutually exclusive "pub- 
lic epitope," Bw4/Bw6  (11,  12).  The limited heterogene- 
ity of this region, with only six different sequences reported 
to  date  (Bw4a-d,  Bw6a,b),  and  the  conservation of these 
motifs  throughout  hominoid  evolution  (13)  suggest  that 
these  sequences  might  have  a  critical function  in  the  im- 
mune response. Indeed, recent data indicate that amino acids 
in this region are involved in the specificity and regulation 
of cytolysis by NK cells (14-16). 
The effect on T  cell function of synthetic peptides corre- 
sponding  to  the  Bw4a/Bw6a  sequences  has  been  further 
analyzed  (17,  18).  Synthetic  peptides  from  both  groups, 
Bw4a (represented by the sequence of the HLA-B2702 al- 
lotype)  and  Bw6a  (represented  by  the  sequence  of  the 
HLA-B0701  allotype),  prevented  the  differentiation  of 
precursors into effector stage CTL. In addition, Bw4a pep- 
tides blocked lysis by established CTL lines. These peptide 
effects were found to be nonallele specific, that is, inhibi- 
tion was  observed for CTL  specific for a  variety of target 
cells expressing different HLA allelic products. Because  of 
these  strong  effects  on  T  cell  function  in  vitro,  peptides 
from both groups were investigated in animal transplanta- 
tion models. Permanent acceptance (tolerance) of heart al- 
lografts was  achieved in rats when  the Bw6a  peptide was 
administered in combination with  subtherapeutic  doses of 
cyclosporin A  (CsA) 1 (19).  Furthermore,  both  the  Bw4a 
and Bw6a peptide prolonged the survival of skin or heart 
allografts when administered as monotherapy (20, 21). 
To  elucidate  the  mechanism  by  which  these  HLA- 
derived peptides  mediate  their  effect  on  T  cells,  experi- 
ments were  designed to identify peptide binding proteins. 
We  found  that  the  inhibitory peptide  B2702  binds  two 
proteins with apparent molecular masses of 70  and 74  kD 
that are members of the heat-shock protein (HSP) 70 fam- 
ily. The binding is sequence specific and restricted to pep- 
tides with T  cell inhibitory activity. The physiologic signif- 
icance  of this  binding  and  the  potential  role  of HSP70 
family members in mediating the T  cell immunornodula- 
tory effects are discussed. 
Materials and Methods 
HLA-derived Peptides.  All peptides  were  synthesized  as  de- 
scribed (17).  The peptides synthesized include (Tables 1 and 2): 
peptides B0701.60-84 and B2702.60-84,  encompassing the entire 
~  Abbreviations  used  in  this paper: BiP; immunoglobulin binding protein; 
B-LCL, B lymphoblastoid cell line; CsA, cyclosporin A; DSG, deox- 
yspergualin; grp, glucose-regulated protein;  HSP, heat~shock protein; 
HSC70, constitutively expressed member of the heat-shock protein 70 
family; HSP70, heat-inducible  member  of the  heat~shock protein  70 
family; NHS,  N-hydroxy-succinimidyl-ester; TNEN,  NP40, Tris-HC1, 
NaC1, EDTA. 
0~1 helix (amino acids 60-84) of the respective HLA class 1 mole- 
cules  (Table  1);  and  peptides B0701.75-84,  B2702.75-84,  and 
B2705.75-84,  representing the  COOH-terminal  halves  (amino 
acids 75-84)  of the former peptides (Table 2).  Amino acid resi- 
dues which comprise the public epitope Bw4a (B2702)  or Bw6a 
(B0701),  respectively, are  underlined  in  Tables  1  and  2.  HLA 
class I  heavy chain  sequences  are  from  Zemmour and  Parham 
(22).  B2702.60-84  and  B2702.75-84  performed  similarly in  in 
vitro  T  cell assays with  some  variability in  the  activity of the 
B2702.75-84 peptide dependent upon the sources of serum used 
in the assays. This variability might be due to the activity of se- 
rum proteases to which the shorter peptides are more susceptible 
than are their longer derivatives. To improve the activity of the 
B2702.75-84  peptide,  dimers  were  synthesized.  B0701.84-75/ 
75-84 and B2702.84-75/75-84  represent inverted repeat dimers 
of amino acids 75-84 of the respective HLA class I molecules and 
peptide B2702.75-84/75-84  is a direct repeat of amino acids 75- 
84  (Table 2).  Direct and inverted repeat dimeric peptides per- 
formed similarly in T  cell assays with slightly enhanced activities 
over the monomeric versions  (not shown).  B2702.84-75T/75- 
84,  B2702.84-75/75-84T,  and  B2702.84-75T/75-84T  contain 
single or double threonine substitutions (Table 2). 
For biochemical analyses,  a biotin group was attached to the 
NH2-terminal  amino  acid  using  N-hydroxy-succinimidyl-ester 
(NHS) activated biotin (NHS-LC-Biotin II; Pierce Chemical Co., 
Rockford, IL). Attachment of the biotin group had no effect on 
the  T  cell  immunomodulatory  activities  of the  peptides  (not 
shown).  Direct and inverted repeat dimeric peptides performed 
similarly in biochemical analyses with slightly enhanced activities 
over the monomeric versions (not shown)  thus correlating with 
the results  of the in vitro T  cell assays. The studies presented in 
this article were performed with the inverted repeat dimeric pep- 
tides, B2702.84-75/75-84  and B0701.84-75/75-84,  abbreviated 
as 02/02 and BT/B7. 
Cells and Antibodies.  PBL  were  isolated  from  the  venous 
blood of healthy donors via Ficoll-Hypaque density centrifuga- 
tion. Cytotoxic T  cell lines (CTL) were established from PBL by 
stimulation with irradiated B-lymphoblastoid cell lines (B-LCL) 
(allogeneic stimulation) (23).  Long-term CTL cultures were car- 
ried in T  cell conditioned medium  (24)  by weekly stimulation 
with irradiated B-LCL. Antibodies specific for various stress pro- 
teins  were  purchased  from  StressGen  (Victoria,  BC,  Canada): 
1t35 (rat IgGla) recognizes the constitutively expressed (HSC70) 
member of the HSP70 family, C92  (mouse IgG1), is specific for 
the  heat-inducible (HSP70)  member of the  HSP70  family and 
N27  (mouse IgG2), which recognizes both HSC70 and HSP70. 
10C3  (mouse  IgG2a)  recognizes the  glucose-regulated proteins 
grp78/immunoglobulin binding protein  (13iP) and  grp94.  The 
anti-grp75 rabbit-polyclonal  antiserum (specific for mitochondrial 
grp75)  was  a  gift from Dr.  W.  Welch  (San  Francisco General 
Hospital,  University of California,  San  Francisco,  CA).  Anti- 
Hsp72  is a mouse ascites  (RPN1197,  IgG1)  (Amersham Corp., 
Arlington Heights, IL) with identical specificity to C92. Isotype- 
matched  antibodies  (Caltag Laboratories, South  San  Francisco, 
CA) were used as controls in immune precipitation assays. 
Heat-Shock  Treatment.  Cells were incubated at 43~  for 1 h 
and allowed to recover for 3 h at 37~  before metabolic labeling 
or precipitations were performed. 
Metabolic Radiolabeling.  For radiolabeling, CTL were used on 
day 4 or 5 after allogeneic stimulation. 3 X 106 ceUs/ml were pre- 
incubated in  methionine/cysteine-free RPMI  1640  (ICN  Bio- 
medical Inc., Costa Mesa,  CA) supplemented with  5% dialyzed 
FCS, 2 mM L-glutamine, and 1.4 mM sodium pyruvate for 1 h. 
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sham Corp.) was added to the culture and the cells further incu- 
bated for 4 h. After radiolabeling, cells were washed twice in ice- 
cold PBS. 
Preparation of Peptide Affinity-matrix.  Saturating amounts ofbio- 
tinylated peptide were incubated with Streptavidin-agarose beads 
(Pierce Chemical Co.) for 2 h at room temperature. Before use in 
precipitation assays, unbound peptide was removed by extensive 
washing in PBS. 
Precipitation of Peptide Binding Proteins.  For  each  precipita- 
tion, 5-7  ￿  106 radiolabeled CTL were used. Cell pellets were 
lysed in 500 b~l of 0.6% CHAPS (3-[(cholamidopropyl)-dimethyl- 
ammonio]-I propanesulfonate)/PBS, pH 7.4, containing protease 
inhibitors, pepstatin (1  ~g/ml), leupeptin (10 ~g/ml), and PMSF 
(0.2 mM) on ice for 30 rain. Cell debris was spun out by micro- 
centrifugation for 10 min at 4~  Peptide binding proteins were 
isolated by incubating cell lysates with peptide/Streptavidin-agar- 
ose beads for 1.5 h at 4~  Where indicated, 5 mM of either ATP 
or yS-ATP (Boehringer Mannheim, Indianapolis, IN) was added 
simultaneously  with  the  peptide  matrix.  After  incubation, 
Streptavidin-agarose beads  were  pelleted  from  the  lysate  and 
washed sequentially in 1 ml each ot~ 0.6%  CHAPS/PBS; TNEN 
(0.5%  NP40,  20 mM Tris-HC1, pH 7.6,  0.1  M  NaCl,  10 mM 
EDTA)  diluted  1:10  in  dH20  and  supplemented with  0.05% 
deoxycholic acid, 0.01% SDS; and a 1:10 dilution of  TNEN con- 
taining 0.5 M  NaC1. 
Precipitation of Stress Proteins.  l~adiolabeled  cell  lysates  were 
incubated with 5 b~l of normal rabbit serum and 250 I*1 of a 10% 
solution of  protein A positive Staphylococcus aureus ceils (Boehringer 
Mannheim)  for 2-4 h  at 4~  (preclearing). S.  aureus cells were 
spun  out and the precleared lysates  immunoprecipitated with 5 
I*g of purified monoclonal antibody or 10 p~l of rabbit antiserum 
or ascites  fluid and 50 b~t of packed protein G-Sepharose beads 
(Pharmacia Biotech  Inc., Alameda, CA)  for  1.5  h  at 4~  Im- 
mune complexes were collected by centrifugation and washed se- 
quentially  in  1  ml  each  oE  TNEN  supplemented  with  SDS 
(0.1%)  and  deoxycholic acid  (0.5%);  TNEN,  diluted  1:10  in 
dH20 and supplemented with 0.5 M  NaCl. 
Electrophoresis.  Precipitated proteins were separated by reduc- 
ing SDS-PAGE (25) or IEF (26). 
Western Blot Analysis.  Peptide binding proteins were precipi- 
tated from unlabeled cell lysates as described above. After separa- 
tion on SDS-PAGE, proteins were transferred to polyvinyldifluoride 
(PVDF)  membrane  (Millipore Corp., Bedford, MA).  Immuno- 
detection using enhanced chemiluminescence (ECL; Amersham 
Corp.) was performed according to the  manufacturer's instruc- 
tion. The membrane was probed first with anti-HSP70 antibody 
(C92,  1:2,000)  and  horseradish  peroxidase-conjugated  anti- 
mouse antibody (i : 5,000).  After ECL detection, the membrane 
was stripped of bound antibodies by incubating it in a solution of 
100  mM  f3-mercaptoethanol/2%  SDS/62.5  mM  Tris-HC1, pH 
6.8, for 30 min at 50~  Then the membrane was reprobed using 
anti-HSC70  antibody  (1B5,  1:5,000)  and  horseradish  peroxi- 
dase-conjugated anti-rat antibody (1 : 5,000). 
One-dimensional Peptide Mapping with  V8 Endoproteinase Diges- 
tion.  P,.adiolabeled protein bands  were  eluted from  nonfixed, 
dried SDS-PAGE gels in PBS/1% SDS over 2 d. After acetone 
precipitation, proteins were solubilized in 40 I*1 of V8 digestion 
buffer (0.125  mM Tris-HC1, pH 6.8, containing 10% glycerol, 1 
mM  EDTA,  0.1%  SDS,  and  0.001%  bromophenol  blue)  and 
loaded onto 15% SDS-PAGE. Digestion was performed "in gel" 
(27, 28) by overlaying the protein solution with 0.5 Ixg of S. au- 
reus V8 endoproteinase (Boehringer Mannheim) and running the 
sample through the stacking gel slowly. At the stacking/sepa- 
rating gel interface, the gel run was interrupted for 30 rain to al- 
low  further  digestion.  Then,  electrophoresis was  performed  as 
usual (25). 
Cell-mediated CytotoxicityAssay.  Cell  killing  was  measured 
using a standard 4-h 51chromium radioisotope release assay (24). 
Briefly, CTL lines specific for allogeneic HLA class I molecules 
were cultured as described above. B-LCLs expressing the HLA 
class I molecule recognized by the CTL line were labeled with 
Slchromium (Amersham Corp.) for 1 h and added to the CTL at 
an effector to target cell ratio such that the percent specific lysis in 
the  untreated samples was  between  30  and  50%.  HLA-derived 
peptides (0-50 ~g/ml) were added to the CTL simultaneously with 
the target cells and remained present during the 4-h incubation. 
All assays were performed in triplicate. The percent specific lysis 
was  calculated by  the  formula:  100  ￿  [(experimental cpm  - 
spontaneous cpm)/(total cpm -  spontaneous cpm)]. Nonbiotiny- 
lated and biotinylated peptides gave identical results. 
Results and Discussion 
The  T  Cell Inhibitory  Peptide B2702  Binds  to Proteins  with 
Apparent Molecular Masses of 74 and 70 kD.  Synthetic  pep- 
tides corresponding to amino acid sequences of the od hehx 
of HLA class I molecules, which overlap the pubhc epitope 
Bw4/Bw6,  were  found  to inhibit T  lymphocyte function 
in vitro  (10,  17,  18)  and to  result in allograft tolerance in 
transplantation models  (19-21).  The  peptide  effects  were 
not allele specific. Therefore,  these HLA-derived peptides 
are  of particular interest in  transplant therapy as  they  can 
potentially be  used  for  all donor-recipient  combinations. 
Peptides with sequences corresponding to the Bw4a epitope 
had the most potent effects in that they inhibited the differ- 
entiation ofT  cell precursors into mature CTL and also in- 
hibited target cell lysis by mature CTL (17,  18). 
Table 1.  Amino Acid Sequences of Synthetic Peptides Encompassing Residues 60-84 of the eel Helix of the HLA-B0701  and HLA-B2702 
Molecules, Respectively 
HLA-derived 
peptide  60  Amino acid residues  84 
B0701.60-84  W  D  tL  N  T  Q  I  Y  K  A  Q  A  Q  T  D  R.  E  S  L  tV  N  L  R.  G  Y 
B2702.60-84  W  D  R  E  T  Q  1  C  K  A  K  A  Q  T  D  R  E  N  L  tL  I  A  L  R  Y 
Underlined are amino acid residues that comprise the pubhc epitopes Bw4a (B2702) and Bw6a (B0701), respectively. 
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Class I Molecules 
HLA-derived  Amino acid residues 
peptide  Abbreviation  position: 75  84 
B0701.75-84  B7  R  E  S  L  R  N  L  R  G  Y 
B2702.75-84  02  R  E  N  L  R  I  A  L  R  Y 
B2705.75-84  05  R  E  D  L  R  T  L  L  R  Y 
B0701.84-75/75-84  B7/B7  Y  G  R  L  N  R  L  S  E  R  R  E  S  L  R  N  L  R  G  Y 
B2702.84-75/75-84  02/02  Y  R  L  A  I  R  L  N  E  R  R  E  N  L  R  1  A  L  R  Y 
B2702.84-75T/75-84  02T/02  Y  R  L  A  T  R  L  N  E  R  R  E  N  L  R  I  A  L  R  Y 
B2702.84-75/75-84T  02/02T  Y  R  L  A  I  R  L  N  E  R  R  E  N  L  R  T  A  L  R  Y 
B2702.84-75T/75-84T  02/02T  Y  R  L  A  T  R  L  N  E  R  R  E  N  L  R  T  A  L  R  Y 
B2702.75-84/75-84  02/02d  R  E  N  L  R  I  A  L  R  Y  R  E  N  L  R  I  A  L  R  Y 
Underlined are amino acid residues that comprise the public epitopes  Bw4a  (B2702) and Bw6a (B070I),  respectively. 
To elucidate the mechanism through  which these HLA- 
derived peptides mediate their T  cell inhibitory effect, pep- 
tide binding proteins were isolated from radiolabeled T  cell 
lysates  using  Streptavidin-agarose  beads  conjugated  with 
biotinylated  peptides.  Precipitations  were  performed  with 
the  inverted  repeat  dimeric  peptides,  B2702.84-75/75-84 
and  B0701.84-75/75-84,  in  parallel.  Two  proteins  with 
molecular  masses  of 70  and  74  kD  were  identified  that 
bound  to  the  inhibitory  peptide  B2702,  but  not  to  the 
noninhibitory  peptide  B0701  (Fig.  1  A).  Additional  bands 
of 78  and  50  kD  were  found  with  both  the  B2702  and 
B0701  peptide  and  also  with  Streptavidin-agarose  in  the 
absence  of any  peptide  (not  shown),  indicating  that  their 
binding is not peptide  dependent.  The precipitation  of the 
74- and  70-kD  proteins was also observed with the mono- 
meric peptides, B2702.60-84  and B2702.75-84,  and the di- 
rect  repeats  of the  B2702  sequence,  B2702.75-84/75-84 
(not  shown).  Reproducibly,  lower intensity  for both  pro- 
tein  bands  was  observed  with  the  monomeric  peptide, 
B2702.75-84.  This correlated with slightly reduced  mhibi- 
Figure 1.  T cell inhibitory  peptide,  B2702, binds to 
74- and 70-kD proteins in an ATP-dependent manner. 
Biosynthetically  labeled  CTL  lysates were  incubated 
with biotinylated  inverted  repeat dimers of the B0701 
(B7/B7) and B2702 (02/02) peptide bound to Strepta- 
vidin-agarose beads. Peptide binding proteins were an- 
alyzed on 8% SDS-PAGE (A). Incubation  in the pres- 
ence  of ATP  (5  mM)  abrogated  precipitation  of the 
74- and 70-kl) proteins by the B2702 peptide, whereas 
yS-ATP had no effect (B). 
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teins correspond to HSC70 and 
HSP70. Peptide binding proteins 
and HSPs (HSC70 and HSP70) 
were precipitated from metaboli- 
caUy labeled long-term CTL ly- 
sates using inverted repeat dimers 
of  the B0701 and B2702 peptide, 
and antibodies, IB5 (specific for 
HSC70)  and  anti-72K  (specific 
for HSP70). Before metabolic la- 
bering, half  of the  culture re- 
ceived  heat treatment (43~ 
Proteins were analyzed on SDS- 
PAGE (.,1) and IEF (/3). (B, +-) 
Bands corresponding to HSC70 
(lane 2, IB5) and HSP70 (lane 4, 
C92). (Lane 3) The precipitation 
pattern  obtained with  the  rat 
IgG1 antibody (isotype control for 1B5). The comparison of precipitation patterns obtained with 1B5 and isotype control antibody helps to segregate 
nonspecific from specific bands for the tB5 antibody. ('ql) Bands present in precipitations with 1B5, C92, and the isotype control antibody, rat/Ig. The 
nature of these bands is unknown. 
tory activity in  CTL  assays  suggesting that  peptide  length 
may be important for both binding to the 74- and 70-kD 
proteins and inhibitory function (our unpublished observa- 
tion; see also Materials and Methods). When the lysis buffer 
was  supplemented  with  ATP,  the  B2702  peptides  no 
longer  bound  to  the  74-  and  70-kD  proteins  (Fig.  1  B). 
The nonhydrolysable ATP derivative, ~S-ATP, had no ef- 
fect, suggesting that ATP hydrolysis abrogates  the binding 
of the B2702 peptide to the 74- and 70-kD proteins. 
Heat-shock treatment  of cells  before metabolic  labeling 
resulted  in  a  dramatic  increase  in  intensity  for the  70-kD 
band and a modest increase for the 74-kD band (Fig. 2 A). 
The  weak  signal  observed  for  the  70-kD  protein  under 
normal growth conditions, therefore, reflects lower quanti- 
ties  of  the  radiolabeled  70-kD  protein  present  in  cells 
grown under normal conditions,  rather than lower affinity 
of the B2702 peptide for the 70-kD protein compared with 
the 74-kD protein. 
The 74- and 70-kD Peptide Binding Proteins Correspond to the 
Constitutively  Expressed (HSC70) and Heat-indudble  (HSP70) 
Members of the HSP70 Family.  Molecular  mass,  regulation 
of binding by ATP, and the upregnlation upon heat-stress 
suggested  that  the  B2702  peptide  binding  proteins  are 
members  of the  HSP70  family.  Different  members  of the 
HSP70 family were precipitated  with respective antibodies 
and  compared  to  the  B2702  peptide  binding  proteins  on 
SDS-PAGE and IEF. Two glucose-regnlated family mem- 
bers,  grp78  and grp75,  were  tested  and found to  differ in 
molecular mass and isoelectric point from the 74- and 70- 
kD peptide  binding proteins  (Fig.  3).  HSC70  and HSP70 
are  two  highly related  family members  that  differ in  their 
expression pattern. HSC70 is expressed constitutively (there- 
fore called HSC70) in all cells  and only moderately upregu- 
lated  upon  heat-shock.  HSP70,  also  called  the  inducible 
family  member,  is  expressed  constitutively  only  in  some 
human cells,  but its expression is highly enhanced upon ex- 
Figure 3.  Peptide  binding proteins are not identical 
to grp75 and grp78/BiP. Peptide binding proteins and 
grp75 and grp78/BiP proteins were precipitated from 
metabolically labeled long-term CTL lysates using bi- 
otinylated inverted repeat dimers of the B070l  (B7/ 
B7) or B2702 (02/02) peptide and antibodies to grp75 
and grp78/BiP (10C3), respectively. Each precipitation 
was split into two aliquots and analyzed  on 8% reduc- 
ing SDS-PAGE (A) or IEF (B). 
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bodies on Western blot. Peptide binding proteins were precipitated from 
unlabeled cellular extracts of long-term CTL using Streptavidin-agarose 
beads with inverted repeat dimers of the B0701 and B2702 peptides, or 
Streptavidin-agarose beads without  any peptide. In addition, total cell 
lysate was separated on 8% SDS-PAGE under reducing conditions. After 
transfer to PVDF membrane, the membrane was sequentially probed, first 
with anti-HSP70 (C92) and second  with anti-HSC70 (1B5). (Arrows)  Posi- 
tions of  the 75-kD peptide binding protein (recognized  by antibody 1B5) 
and the 70-kD peptide binding protein (recognized  by antibody C92). 
posure  to  high  temperature.  The  74-  and  70-kD  peptide 
binding proteins  closely resemble  the  HSC70  and  HSP70 
proteins in electrophoretic mobility on SDS-PAGE (Fig. 2 
A) and IEF (Fig. 2/3) and display identical response to heat 
(Fig.  2  A).  Furthermore,  in Western  blot  analysis  the  74- 
kD  peptide  binding protein  was recognized by  1B5  (spe- 
cific  for HSC70)  and  the  70-kD  peptide  binding protein 
was recognized by C92 (specific for HSP70)  (Fig. 4). Thus, 
the  74-  and  70-kD  peptide  binding proteins  appeared  to 
correspond  to  HSC70  and  HSP70  proteins,  respectively. 
This  hypothesis  was  confirmed by digestion  with  V8  en- 
doproteinase,  which  created  identical  patterns  for the  74- 
kD protein and HSC70 and the 70-kD protein and HSP70 
(Fig. 5). 
Peptide  Binding  to  HSC/HSP70  Is  Sequence Specific and 
Correlates with  the  Peptide  Effects on  T  Lymphocyte  Function. 
HSP70  family  members  are  known  to  bind  peptides  and 
the binding motifs have  been  described  recently  (29).  Al- 
ternating  hydrophobic  or  aromatic  residues  with  relative 
positions 2,  4, and 6  (P2,  P4,  P6)  in the peptide  sequence 
were  defined  as  a  motif.  In  addition,  HSC70  favors  the 
binding  of peptides  with  positively  charged residues.  The 
B2702 peptide sequence, RENLRIALRY  (Table 2), fulfills 
these binding requirements  precisely.  The amino acid resi- 
dues underlined  (L,  I, L) correspond to the defined hydro- 
phobic anchors, P2, P4, and P6, of the binding motif. The 
B0701 peptide  sequence, RESLNRLRGY  (Table 2),  does 
not  match  the  binding  motif.  Furthermore,  Fourie  et  al. 
(29) showed that amino acid substitutions at position 4  (P4) 
in  the  peptide  sequence  in  particular  resulted  in  signifi- 
cantly reduced binding affinity, indicating position 4 as the 
main anchor position.  Aligning the B2702  sequence  to fit 
the  binding  motif,  the  isoleucine  residue  corresponds  to 
position P4 and is likely to be the main anchor residue for 
the  B2702  peptide.  This  hypothesis  was  confirmed  by 
binding studies.  Exchanging the first isoleucines for threo- 
nine in the B2702.84-75/75-84 inverted repeat peptide re- 
suited in slightly reduced binding to HSC/HSP70.  Signifi- 
cantly  reduced  binding  was  observed  when  the  second 
isoleucine was replaced by threonine and exchanging both 
isoleucines  resulted  in  a  peptide,  B2702T/T,  which  no 
longer  bound  to  HSC70  or  HSP70  (Fig.  6).  Thus,  the 
binding motif provides an explanation for the failure of the 
B0701  and B2702T/T  peptides  to precipitate  the  74- and 
70-kD molecules. 
Most interesting, however, is that the importance ofiso- 
leucine  in  the  peptide  sequence  had  previously been  de- 
fined  functionally  by  comparing  peptides  derived  from 
closely  related  HLA-B27  allotype  sequences  (17).  HLA- 
B2702  and  HLA-B2705  are  closely  related  proteins  that 
differ by only three  amino acids in the cll  helix  (Table  2). 
Synthetic  peptides  corresponding  to  that  region  were  in- 
vestigated  in  in  vitro  T  cell  assays  and  the  B2705  peptide 
was found ineffective whereas the B2702 peptide  inhibited 
T  cell function (17). When the B2705 amino acid residues 
were  singly introduced  into  the  B2702  peptide  sequence, 
Figure 5.  V8 digestion creates 
identical peptide patterns for the 
74- and 70-kD peptide binding 
proteins and HSC70 and HSP70, 
respectively. Proteins were pre- 
cipitated from metabolically la- 
beled CTL lysates and separated 
on 8% SDS-PAGE. After detec- 
tion  by  autoradiography, bands 
corresponding to peptide bind- 
ing  proteins,  74  and  70  kD, 
HSC70  (precipitated with anti- 
body 1B5) and HSP70 (precipi- 
tated with  antibody C92) were 
excised,  eluted,  and  reelectro- 
phoresed on 15% SDS-PAGE in 
the presence of 0.5  Ixg V8  en- 
doproteinase. 
Figure 6.  Substitution of isoleucine for threonine abrogates peptide 
binding to HSC70 and HSP70. Inverted repeat dimers of  the B2702 pep- 
tide and its single and double threonine-substituted derivatives, 02/02T, 
02T/02, and 02T/02T, were used to precipitate peptide binding proteins 
from metabolically  labeled long-term CTL total cell extracts. 
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Figure 7.  Amino acid isoleucine is critical for the 
inhibition of cytolysis by the B2702 peptide. An 
HLA-A2 restricted CD8 § CTL line was tested for 
its ability to lyse Slchromium-labeled HLA-A2 ex- 
pressing B-LCL, JY.  The E/T cell ratio was 2 : 1 
and resulted in a specific lysis of ~35% for the un- 
treated sample. Inverted repeat dimers of  the B0701 
and B2702 peptides, as well as the single and dou- 
ble threonine-substituted derivatives of the B2702 
peptide were added at the indicated concentrations 
at the beginning of the 4-h assay. Each time point 
represents the mean of  triplicate. This experiment is 
a representative of five independent assays using 
HLA-A2, -B43, -B27, or -Cw4 specific CTL lines. 
only the substitution ofisoleucine for threonine at position 
80 caused a loss of the functional effects. The effect of sub- 
stituting  the  isoleucine  residue  was further analyzed using 
the  inverted  repeat  peptide,  B2702.84-75/75-84.  The in- 
hibitory effect was reduced when  one  or the  other of the 
isoleucines was replaced for threonine and exchanging both 
the isoleucines resulted in a complete loss of function (Fig. 
7).  This loss of function correlated strictly with the loss of 
binding to the HSC/HSP70 proteins (Fig. 6 and Table 3). 
The  binding  of  B2702  peptides  and  not  B0701  or 
B2702T/T  peptides  to  HSC/HSP70  proteins  can  be  ex- 
plained  on the basis  of the  defined HSC70 binding motif. 
Most intriguing,  however,  is  the  correlation  between  the 
functional effects and the binding to HSC/HSP70.  With- 
out  exception  to  date,  peptides  with  T  cell inhibitory  ef- 
fects bind to HSC/HSP70, whereas noninhibitory peptides 
do not bind.  This  correlation  suggests that  the binding to 
HSC/HSP70 might be of physiological relevance and may 
be  involved  in  mediating  the  T  cell  immunomodulatory 
effect of the HLA-derived B2702 petpide. 
Peptide-mediated  Immunomodulation  and the  Potential Roles 
for HSPs.  Consistent with the broad expression of HSC/ 
HSP70  proteins,  the  74/70-kD  peptide  binding  proteins 
were found in whole cell lysates of all cell types studied, in- 
cluding B-LCL,  T  cell tumor lines,  HeLa,  a preerythroid 
Table 3.  Peptide  Binding to HSC70/HSP70 Correlates with 
Peptide Function 
Inhibition of  Binding to 
Peptide  T cell function  HSC70/HSP70 
02/02  + + +  + + + 
02T/02  + +  + + 
02/02T  +  +/- 
02T/02T  -  - 
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cell  line  (K562),  and  an  endothelial  cell  line  (SK-HEP1) 
(not shown). The T  cell-specific peptide effect must, there- 
fore, be due to an additional mechanism not found in other 
cell types. Indicative of such a T  cell-specific mechanism is 
the observation that, when intact cells were incubated with 
the  B2702  peptides,  HSC/HSP70  proteins  were  isolated 
only from T  lymphocytes and CTL. One possible explana- 
tion for this  finding is  that  HSC/HSP70  are  expressed  at 
the  surface  of the  T  cells  and  that  the  binding  of HLA- 
derived peptides  to these surface HSPs initiates  signals that 
inhibit  T  cell  function.  Surface  expression  of HSP70  has 
been  reported  for  antigen-presenting  cells  (B  cells  and 
monocytes) and some tumor cells, but not for T  cells  (30- 
34).  Similarly,  we find no evidence for surface  expression 
of HSC70 or HSP70 on the affected T  cells using cytofluo- 
rimetric  analyses  and  monoclonal  antibodies  specific  for 
HSP70  (C92,  N27,  anti-Hsp72)  or  HSC70  (1B5,  N27) 
(not shown). Based upon the lack of evidence for cell sur- 
face  expression  of HSP70  on  T  cells,  we  do  not  favor a 
model in which HLA-derived peptides mediate their T  cell 
inhibitory  activity by signaling through cell surface  HSPs. 
We proposed that HLA-derived peptides function intracel- 
lularly much like  other immunosuppressive  reagents,  such 
as CsA and FK506, with a role for HSC/HSP70 similar to 
immunophilins,  FKBP  and  CyP40  (see  below).  Within 
such  a  model,  the  observation  that  HSC/HSP70  binding 
was only observed for T  cells when intact  cells  were used 
might indicate T  cell-specific uptake mechanisms that pro- 
mote peptide access to the cytosolic HSPs. 
HSPs and Immune Suppression.  The role of HSPs in an- 
tigen presentation and tumor immunity is currently an area 
of intense  investigation  (33,  35-38).  Of particular interest 
in this  context is the  observation that an immunosuppres- 
sive  drug,  deoxysperguahn  (DSG),  was  found  to  bind  to 
HSC70 (39). Recently, it has been demonstrated that DSG 
exerts  its  immunosuppressive  activity  at  the  level  of the 
monocytes,  apparently  by  interfering  with  their  antigen 
presentation  function  (40).  Therefore,  the  DSG  system provides  substantiating  evidence  for the  hypothesis  previ- 
ously proposed by Srivastava et al.  (38)  implicating HSP70 
in antigen presentation pathways. 
DSG and the HLA-derived B2702 peptide, although ap- 
parently binding to the same ligand HSC70,  differ in their 
immunomodulatory  activity.  First,  the  HLA-derived  pep- 
tide inhibits allospecific cytotoxic T  ceils and inhibits T  cell 
proliferation  (our unpublished  observation),  whereas  DSG 
does  not  inhibit  cytolysis.  Second,  the  effects  of HLA- 
derived peptides are exerted at the level of the T  cell, not at 
the level of the antigen-presenting  cell as demonstrated for 
DSG  (40).  Combined,  these differences suggest that HLA- 
derived  peptides  mediate  immunosuppression  through  a 
mechanism different than that described for DSG, and that 
the role of HSC/HSP70  in the peptides' immunomodula- 
tion does not involve antigen presentation. 
Other  immunosuppressive  compounds,  such  as  FK506, 
CsA,  and  rapamycin,  mediate  immune  suppression  by in- 
terfering with signaling events required for T  cell activation 
(41).  CsA  and  FK506  both  target  an  intracellular  phos- 
phatase,  calcineurin,  a key enzyme in the signaling cascade 
resulting in IL-2 transcription  and T  cell proliferation  (42- 
44).  Inhibition  of calcineurin  activity and hence immuno- 
suppression  is dependent  upon the formation of a complex 
between the drug and an immunosuppressant binding pro- 
tein.  Two  classes  of immunosuppressant  binding  proteins, 
FKBPs  (for FK506  binding proteins)  and  cyclophilins  (for 
CsA  binding  proteins),  collectively  called  immunophilins, 
have been  identified.  They are  abundantly  expressed  pro- 
teins  that  are  conserved  throughout  evolution.  They  are 
found in different isoforms and are localized to various sub- 
cellular  compartments.  In addition,  both  exhibit  rotamase 
activity and  are postulated  to be involved in protein  fold- 
ing, reduction  of protein aggregates,  and protein transloca- 
tion  (45).  These  characteristics  also  apply  to  the  HSP70 
family  (46).  Combined,  the  biochemical  similarities  be- 
tween immunophilins  and HSP70 proteins and the finding 
that  HSP70  family  members  bind  imnmnosuppressive 
compounds,  DSG  (39)  and  the  HLA-derived  B2702  pep- 
tide,  indicate  that HSP70 family members may represent a 
third  class  of  immunophilins.  Therefore,  we  propose  a 
function for the HLA-derived B2702  peptide analogous to 
the  mode  of action  of CsA  and  FK506  with  a  role  for 
HSC/HSP70  similar  to  that  of immunophilins,  such  as 
CyP40 and FKBP.  The definition  of an intracellular  target 
protein for the peptide-HSC70  complex, analogous to cal- 
cineurin,  will  be  necessary  to  provide  substantiating  evi- 
dence for the proposed model. 
The analysis ofimmunosuppressive compounds like CsA 
and FK506 has substantially increased our understanding  of 
signal pathways involved in T  lymphocyte activation  (41). 
Investigations  on  the  mechanism  by  which  the  HLA- 
derived  peptides  mediate  their  immunomodulatory  effects 
will further  extend  our knowledge  about T  cell activation 
and the  regulation  of T  cell effector function.  In addition, 
the  results  of these  studies  may provide  new  insights  into 
the  development  of novel immunotherapeutics  capable  of 
inducing immunologic tolerance. 
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